Publications
LimmaTech Biologics has established a leadership position in applying various technologies to discover, develop and produce vaccines addressing a range of infectious diseases, particularly those caused by pathogens with a high risk of antimicrobial resistance.
Identification of a second glycoform of the clinically prevalent O1 antigen from Klebsiella pneumoniae
Steven D. Kelly, Olga G. Ovchinnikova, Fabian Müller, Michael Steffen, Martin Braun, Ryan P. Sweeney, Michael Kowarik, Rainer Follador, Todd L. Lowary, Fabio Serventi, and Chris Whitfield
Edited by Joe Lutkenhaus, University of Kansas Medical Center, Kansas City, KS; received January 26, 2023; accepted May 15, 2023
→ read
Immunization of Rabbits with a Quadrivalent Shigella Bioconjugate Vaccine Induces Functional Antibodies Reactive with Shigella Isolates from Kenya
Elizabeth A. Odundo, Hailey P. Weerts, Lillian Musila, Lilian Ogonda, Anita M. Dreyer, Joerg Schneider, Paula Carranza, Robert W. Kaminski. Published 25 May 2022
→ read
The Development of Immunological Assays to Evaluate the Level and Function of Antibodies Induced by Klebsiella pneumoniae O-Antigen Vaccines
Helen R. Wagstaffe, Maria Johnson, Guled Osman, Patricia Martin, Paula Carranza, David Goldblatt. Published 6 March 2023
→ read
The Ongoing Journey of a Shigella Bioconjugate Vaccine
Patricia Martin, Cristina Alaimo, Academic Editors: Duncan Steele and Calman A. MacLennan. Published 29 January 2022
→ read
The development and characterization of an E. coli O25B bioconjugate vaccine
Michael Kowarik, Michael Wetter, Micha A. Haeuptle, Martin Braun, Michael Steffen, Stefan Kemmler, Neil Ravenscroft, Gianluigi De Benedetto, Matthias Zuppiger, Dominique Sirena, Paola Cescutti & Michael Wacker. Published: 17 March 2021
→ read
Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine
Kristen A Clarkson, Kawsar R Talaat, Cristina Alaimo, Patricia Martin, A Louis Bourgeois, Anita Dreyer, Chad K Porter, Subhra Chakraborty, Jessica Brubaker, Daniel Elwood, Rahel Frölich, Barbara DeNearing, Hailey P Weerts, Brittany Feijoo, Jane Halpern, David Sack, Mark S Riddle, Veronica Gambillara Fonck, Robert W Kaminski. Published: April 02, 2021. DOI: https://doi.org/10.1016/j.ebiom.2021.103308
→ read
Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection
Kawsar R. Talaata, Cristina Alaimo, Patricia Martin, A. Louis Bourgeois, Anita M. Dreyer, Robert W. Kaminski, Chad K. Porter, Subhra Chakraborty, Kristen A. Clarkson, Jessica Brubaker, Daniel Elwood, Rahel Frölich, Barbara DeNearing, Hailey Weerts, Brittany L. Feijoo, Jane Halpern, David Sack, Mark S. Riddle, Veronica Gambillara Fonck. Published: April 12, 2021. DOI: https://doi.org/10.1016/j.ebiom.2021.103310
→ read
The development and early clinical testing of the ExPEC4V conjugate vaccine against uropathogenic Escherichia coli
Huttner A, Gambillara V 2018 Oct;24(10):1046-1050. doi: 10.1016/j.cmi.2018.05.009. Epub 2018 May 24.
→ read
Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial
Angela Huttner, Christoph Hatz, Germie van den Dobbelsteen, Darren Abbanat, Alena Hornacek, Rahel Frölich, Anita M Dreyer, Patricia Martin, Todd Davies, Kellen Fae, Ingrid van den Nieuwenhof, Stefan Thoelen, Serge de Vallière, Anette Kuhn, Enos Bernasconi, Volker Viereck, Tilemachos Kavvadias, Kerstin Kling, Gloria Ryu, Tanja Hülder, Sabine Gröger, David Scheiner, Cristina Alaimo, Stephan Harbarth, Jan Poolman, Veronica Gambillara Fonck. Published: 23 February 2017
→ read
Safety and Immonogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study
Riddle MS, Kaminski RW, Di Paolo C, Porter CK, Gutierrez RL, Clarkson KA, Weerts HE, Duplessis C, Castellano A, Alaimo C, Paolino K, Gormley R, Gambillara Fonck V. Clin Vaccine Immunol. 2016 Dec 5;23(12):908-917
→ read
Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models
van den Dobbelsteen G, Faé KC, Serroyen J, van den Nieuwenhof I, Braun M, Haeuptle M, Sirena D, Schneider J, Alaimo C, Lipowsky G, Gambillara-Fonck V, Wacker M, Poolman JT. Vaccine. 2016 Jul 29;34(35):4152-60
→ read
Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study
Hatz CF, Bally B, Rohrer S, Steffen R, Kramme S, Siegrist CA, Wacker M, Alaimo C, Fonck VG. Vaccine. 2015 Jul 7. pii: S0264-410X(15)00919-6.
→ read
Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli
Wacker M, Wang L, Kowarik M, Dowd M, Lipowsky G, Faridmoayer A, Shields K, Park S, Alaimo C, Kelley KA, Braun M, Quebatte J, Gambillara V, Carranza P, Steffen M, Lee JC. J Infect Dis. 2014 May 15;209(10):1551-61.
→ read
Definition of the bacterial N-glycosylation site consensus sequence
Kowarik M, Young NM, Numao S, Schulz BL, Hug I, Callewaert N, Mills DC, Watson DC, Hernandez M, Kelly JF, Wacker M, Aebi M. EMBO J. 2006 May 3;25(9):1957-66.
→ read
Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli
Feldman MF, Wacker M, Hernandez M, Hitchen PG, Marolda CL, Kowarik M, Morris HR, Dell A, Valvano MA, Aebi M. Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3016-21.
→ read
N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli
Wacker M, Linton D, Hitchen PG, Nita-Lazar M, Haslam SM, North SJ, Panico M, Morris HR, Dell A, Wren BW, Aebi M. Science. 2002 Nov 29;298(5599):1790-3.
→ read